Replacing Invasive Cystoscopy with Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance  (Replace Cysto)

This is a multi-site randomized phase 2 trial including 240 patients with early- stage bladder cancer, in which patients will be randomized 1:1:1 to programmatic surveillance with the Xpert bladder cancer urine test, the Bladder EpiCheck urine test, or frequent cystoscopy. The primary outcome will be urinary quality of life 1 to 3 days after surveillance 

Principal Investigator: Dr. Lewis Thomas
Study Coordinators: Carley Browning and Joe Manacop 


This study is in the final stages of regulatory approval and will be recruiting participants soon.
To learn more about Replace Cysto and how you can join contact our research office at (314) 289-7690

This study is funded by the Foundation through the NCI (National Cancer Institute)